China 
Africa 
Explore chapters and articles related to this topic
Biocompatible and Bioactive Ceramics for Biomedical Applications
Published in Atul Babbar, Ranvijay Kumar, Vikas Dhawan, Nishant Ranjan, Ankit Sharma, Additive Manufacturing of Polymers for Tissue Engineering, 2023
Figures 4.3 and 4.4 represent the word cloud of the top 30 author keywords and the tree plot of author keywords. The author keyword hydroxyapatite has a significant role in the research as the authors provided it and appeared 23 times with a contribution of 18%. Bioactivity has appeared ten times with a contribution of 8%, followed by bioactive ceramics and mechanical properties with 5% appearance. The terms scaffolds and composite have a minor contribution. Many of the author keywords have the same meaning but are presented by the authors with little difference. Tissue engineering is a biotechnology field that uses a combination of cells, materials sciences, and appropriate biochemical and physiochemical parameters to recover, sustain, upgrade, or substitute biological tissues (Moreno Madrid, Vrech, Sanchez, & Rodriguez, 2019; Shick, Abdul Kadir, Ngadiman, & Ma’aram, 2019). The ability of materials to form a straight, persistent, and deep connection with bone tissue is referred to as bioactivity (Prakash, Singh, Pabla, & Uddin, 2018).
Status of Nigeria's Biosafety Regulation
Published in Sylvia Uzochukwu, Nwadiuto (Diuto) Esiobu, Arinze Stanley Okoli, Emeka Godfrey Nwoba, Christpeace Nwagbo Ezebuiro, Charles Oluwaseun Adetunji, Abdulrazak B. Ibrahim, Benjamin Ewa Ubi, Biosafety and Bioethics in Biotechnology, 2022
Rufus Ebegba, Scholastica Bello, Joy Onwude
Irrespective of the potential benefits of modern biotechnology, there are concerns that these products have potential adverse effects on human, plant and animal health, biological diversity and the environment. Also, there are several important socio-economic, cultural and ethical issues to be considered in the adoption and use of the products of modern biotechnology. As a result of these concerns, the Cartagena Protocol on Biosafety (CPB) was adopted in Montreal on 29 January 2000 at an extraordinary meeting of the Conference of the Parties to the CBD. The CPB makes provisions to regulate, manage or control risks associated with transfer, handling and use of organisms and derived products resulting from modern biotechnology that may have adverse effects on conservation and sustainable use of biological diversity, taking into account risks to human health, focusing on their transboundary movement (CPB, 200).
Careers in Biotechnology
Published in Firdos Alam Khan, Biotechnology Fundamentals, 2020
Biotechnology is an emerging field that keeps on expanding with arrays of opportunities and challenges, especially in terms of finding out new methods and better treatment modalities for various human ailments, protecting the environment, reestablishment of extinct species, enhancing crops and food products, and finding out alternative and eco-friendly energy sources. One can imagine the impact of biotechnology on everyday life. It has now become obvious to think about how we can shape our career in various areas of biotechnology.
Technological development and patent analysis: the case of biopharmacy in the world and in Latin America
Published in Tapuya: Latin American Science, Technology and Society, 2022
Alejandro Barragán-Ocaña, Rubén Oliver-Espinoza, María del Pilar Longar-Blanco, Hortensia Gómez-Viquez
The new paradigm represented by the integration of the pharmaceutical industry and biotechnology is a central element in the development of new therapeutic and prophylactic solutions and diagnostic applications that allow for innovative approaches and solutions to treat multiple diseases and ailments in which the pharmaceutical sector’s success has traditionally been limited. Remarkable scientific and technological advances have occurred over the past decades, and the transversality of biotechnology has allowed for a wide range of solutions in different areas such as health care, agriculture, food production, and environmental protection, among others. Additionally, advances in other disciplines such as microbiology, virology, genetics, and molecular biology, to name a few, have resulted in new medical applications based on the use of biotechnology that reveal important and unprecedented progress.
The ambivalent regulator: the construction of a regulatory style for genetically modified crops in Chile
Published in Tapuya: Latin American Science, Technology and Society, 2019
Maite P. Salazar, Daniel Valenzuela, Manuel Tironi, Rodrigo A. Gutiérrez
Regulation is integral to the configuration of any technology. In its most general definition, regulation connotes a form of rule or directive made and maintained by an authority (Black 2002). In the case of biotechnology, regulation can be defined as the vehicle through which states provide assurance that the political, economic, and environmental risks of new technologies can be contained within manageable bounds (Jasanoff 1995). The scope, content, and contentiousness of biotech innovations vary significantly depending on their regulatory contexts. Regulation is therefore an interface between technoscientific inventions and society at large. As Jasanoff puts it, regulation “is a kind of social contract that specifies the terms under which state and society agree to accept the costs, risks and benefits of a given technological enterprise” (1995, 311).
Anomaly handling and the politics of gene drives
Published in Journal of Responsible Innovation, 2018
Sam Weiss Evans, Megan J. Palmer
When the US Coordinated Framework for Regulation of Biotechnology was developed in 1986, it included a set of tenets intended to ensure public safety without overburdening the fledgling biotechnology industry with regulation. These tenets include (1) focusing regulation on the products of GM techniques rather than the process itself; (2) grounding regulation in verifiable scientific risks; and (3) placing GM products on a continuum with existing products such that existing statutes are sufficient to review the products (Marden 2003, 738). These tenets look different from those of other regulatory environments, such as the European Union, which focus more on the process, creating rules and authorities specific to GM (Jasanoff 2005a).